Members area 
Members area 
Short Bowel Syndrome—Pre-Market Entry Study
Task:
To assess the opportunity of accessing the local market.
Task:
To assess the opportunity of accessing the local market.
Client:
EU-based Market Access consultancy.
Region:
Ukraine
Product in focus:
Teduglutide brand—the first and only long-term therapy indicated for the treatment of patients with SBS-IF (orphan disease).
Project areas:
- Analysis of the country's short bowel syndrome-intestinal failure (SBS-IF) market.
- Assessment of the existing competitive environment in the core market.
- Identification of the total patient population for the targeted indication.
- Estimation of time to achieve public funding.
- Overview of the public funding of medicines in Ukraine.
- Overview of the situation concerning the country's public funding of orphan drugs.
- Mapping decision-makers in the area of demand forming for orphan drugs in Ukraine.
Deliverables:
- Detailed report on the Short Bowel Syndrome in Ukraine.
- Regulatory environment overview.
- Pricing & Reimbursement status.
- Map of key stakeholders and decision-makers.
Project
leads
Yevgen Brovko
Co-founder, Market Access Partner (Pharmac/Biopharma, MedTech, Digital Health)
Download
our Brochure
our Brochure